Printer Friendly

LIPOSOME COMPANY REPORTS THIRD QUARTER RESULTS; THIRD QUARTER REVENUES UP 151.6 PERCENT

        LIPOSOME COMPANY REPORTS THIRD QUARTER RESULTS;
           THIRD QUARTER REVENUES UP 151.6 PERCENT
    PRINCETON, N.J., Nov. 6 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO) today reported total revenues for the third quarter ended Sept. 30, 1991, were $2,506,000, a 151.6 percent increase over the third quarter of 1990.  The net loss for the quarter was $715,000, a decrease of 62 percent compared to the loss of $1,890,000 in the same quarter a year ago.  The net loss per share was 4 cents versus a loss of 13 cents in the third quarter a year ago.
    Revenues received under two major licensing agreements signed in the fourth quarter of 1990 -- an agreement with Pfizer Inc covering TLC D-99 (liposomal doxorubicin) and an agreement with Schering AG of Berlin, Germany for TLC I-16, a liposomal non-ionic contrast agent -- accounted for the majority of the increase in collaborative research and development revenue to $1,517,000 as compared to $835,000 a year ago. In addition, interest income increased $680,000 or 469 percent due to the investment of proceeds from a second quarter 1991 stock offering. Licensing and other fees increased $148,000 due to an increase in gross profits earned by the company's Princeton Lipids division and a one-time licensing fee earned in the third quarter.
    Total expenses for the quarter ended Sept. 30, 1991, were $3,221,000, and increase of 11.6 percent versus the third quarter of 1990.  This increase was due to the higher level of manpower and supplies required for clinical trials of the company's lead products and preclinical testing of TLC C-53, a cell adhesion antagonist being developed for Adult Respiratory Distress Syndrome (ARDS) and Reperfusion Injury following Acute Myocardial Infarction (AMI) or heart attacks.  In addition, general and administrative expenses increased by $188,000 compared to the third quarter of 1990.
    Revenues for the nine months ended Sept. 30, 1991, were $6,213,000, an increase of $3,193,000 or 105.7 percent compared to the nine months ended Sept. 30, 1990.  Total expenses for the period were $9,221,000, an increase of $652,000 or 7.6 percent as compared to the first nine months of 1990.  Overall, the net loss for the nine months ended Sept. 30, 1991, of $3,008,000 represents a decrease of $2,541,000 or 45.8 percent over the nine months ended Sept. 30, 1990.  The net loss per share for the first nine months of 1991 was 17 cents versus a loss of 39 cents per share in the same period a year ago.
    The largest company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, The Liposome Company selectively develops proprietary parenteral pharmaceuticals for the treatment and diagnosis of life-threatening illnesses.  The Liposome Company's most advanced products treat cancer and serious bacterial and fungal infections in immunocompromised patients, such as those with cancer and AIDS.
                      THE LIPOSOME COMPANY, INC.
                 Consolidated Statements of Operations
               (In thousands, except per share figures)
                           (Unaudited)
     Periods ended               Three Months         Nine Months
     Sept. 30;                  1991    1990         1991     1990
    Collaborative research and
     development revenues     $1,517    $835        $4,277   $2,368
    Licensing and other fees     164      16           233      106
    Interest income              825     145         1,703      546
    Total revenues             2,506     996         6,213    3,020
    Research and development
     expenses                  2,327   2,180         6,685    6,195
    General and administrative
     expenses                    894     706         2,536    2,374
    Total expenses             3,221   2,886         9,221    8,569
    Net loss                    (715) (1,890)       (3,008)  (5,549)
    Net loss per common share   (.04)   (.13)         (.17)    (.39)
    Weighted average number of
     common shares
     outstanding              19,451  14,227        17,760   14,213
            Consolidated Statements of Financial Condition
                          (In thousands)
     Period ended                   9/30/91        12/31/90
                                  (unaudited)      (audited)
    Current assets, principally
     cash and short-term
     investments                   $48,176          $8,220
    Property and equipment, net      1,843           1,711

    Other assets, net                1,596           1,076
    Total assets                    51,615          11,007
    Current liabilities              3,301           2,914
    Other liabilities                  614             658
    Stockholders' equity            47,700           7,435
    Total liabilities and
     stockholders' equity           51,615          11,007
    -0-                11/6/91
    /CONTACT:  Anne M. Van Lent, senior vice president and CFO of The Liposome Company, 609-452-7060/
    (LIPO) CO:  The Liposome Company, Inc. ST:  New Jersey IN:  MTC SU:  ERN PS-FC -- NY004 -- 1545 11/06/91 09:00 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 6, 1991
Words:734
Previous Article:CIRCUIT CITY STORES, INC. REPORTS OCTOBER SALES
Next Article:GEOPHYSICAL CONSORTIUM SELECTS INTEL SUPERCOMPUTER FOR PARALLEL SEISMIC PROCESSING
Topics:


Related Articles
THE LIPOSOME COMPANY REPORTS FOURTH QUARTER AND YEAR END RESULTS
LIPOSOME REPORTS SECOND QUARTER RESULTS; SECOND QUARTER REVENUES UP 31 PERCENT
THE LIPOSOME COMPANY, INC. REPORTS THIRD QUARTER RESULTS; THIRD QUARTER REVENUES UP 11 PERCENT
THE LIPOSOME COMPANY, INC. REPORTS FOURTH QUARTER AND YEAR END RESULTS; YEAR HIGHLIGHTED BY PROGRESS IN CLINICAL TRIALS AND MANUFACTURING
THE LIPOSOME COMPANY, INC. REPORTS SECOND QUARTER RESULTS
THE LIPOSOME COMPANY, INC. REPORTS THIRD QUARTER RESULTS
THE LIPOSOME COMPANY, INC. ANNOUNCES PRELIMINARY FIRST QUARTER RESULTS IN LINE WITH EXPECTATIONS
THE LIPOSOME COMPANY, INC. REPORTS SECOND QUARTER RESULTS
THE LIPOSOME COMPANY, INC. REPORTS THIRD QUARTER RESULTS
The Liposome Company Reports Third Quarter Operating Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters